Get the Stockscreener App
48.25
1.75%
-0.86
Pre-market:
49.21
0.96
+1.99%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $48.25, with a volume of 28.37M.
It is down -1.75% in the last 24 hours and down -19.08% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$49.11
Open:
$47.96
24h Volume:
28.37M
Relative Volume:
1.87
Market Cap:
$163.57B
Revenue:
$45.45B
Net Income/Loss:
$16.18B
P/E Ratio:
13.29
EPS:
3.6297
Net Cash Flow:
$8.96B
1W Performance:
-7.30%
1M Performance:
-19.08%
6M Performance:
-30.30%
1Y Performance:
-56.02%
1-Day Range:
$47.76
$49.90
1-Week Range:
$47.76
$52.80
52-Week Range:
$45.05
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.25 | 218.22B | 45.45B | 16.18B | 8.96B | 3.6297 |
|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues - GlobeNewswire Inc.
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
Multi asset correlation models including Novo Nordisk A s (b Shares) Adrhedged2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk Stock Is Falling Friday: What's Driving The Action? - Sahm
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Sahm
What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem - Sahm
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm
Novo Nordisk layoffs: Pharma major begins job cuts in US amid fierce weight-loss drug battle — Here's what we know - livemint.com
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm
Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations - Sahm
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm
UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail
BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Portnoy Law Firm Announces Class Action on Behalf of Novo Nordisk A/S Investors - GlobeNewswire
Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa
Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):